Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Recruiting 28Active not recruiting 15Completed 7Not yet recruiting 4Terminated 3Withdrawn 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 2Metastatic Castration Resistant Prostate Cancer 1

Interventions

Cyclophosphamide 390Carboplatin 343Gemcitabine 331pembrolizumab 330Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 286Bevacizumab 249Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 189fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 127Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 119Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Interventional × Pluvicto × Clear all
NCT06516510 2025-09-25

A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

Blue Earth Therapeutics Ltd

Phase EARLY_PHASE1 Terminated
17 enrolled
Genitourinary

Prostatic Neoplasms

NCT03545165 2021-08-24

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

Weill Medical College of Cornell University

Phase 1/2 Terminated
6 enrolled 24 charts
Genitourinary

Prostatic Neoplasms

NCT03042312 2021-03-24

RESIST-PC

Endocyte

Phase 2 Terminated
71 enrolled 15 charts
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡